Trial Search Results

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

This research trial studies a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. Gathering health information about patients with acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Other: Cytology Specimen Collection Procedure
  • Other: Laboratory Biomarker Analysis


Inclusion Criteria:

   - Patient has newly diagnosed acute leukemia:

      - > 25% blasts on a bone marrow (BM) aspirate or

      - If a BM aspirate is not obtained or is not diagnostic of acute leukemia, the
      diagnosis can be established by a pathologic diagnosis of acute leukemia on a BM
      biopsy or

      - A complete blood count (CBC) documenting the presence of at least 1,000/uL
      circulating leukemic blasts

   - Adequate samples must be provided to the reference and/or COG-approved cytogenetics
   laboratories to allow completion of the studies needed for risk-stratification

      - If a BM aspirate is not performed, or adequate material cannot be obtained,
      peripheral blood (PB) can be substituted for BM if there are at least 1,000
      circulating blasts/uL (i.e., a white blood cell [WBC] count of 10,000/uL with 10%
      blasts or a WBC count of 5,000/uL with 20% blasts); if only PB is submitted,
      please obtain and send twice the volume of PB as the recommended BM volume
      specified; the patient will remain on AALL08B1 as long as all required central
      laboratory tests can be successfully performed; as long as there are at least
      1,000/uL PB blasts, institutions are encouraged to submit PB in addition to BM
      samples to make sure that adequate material is available to perform the required

      - If an adequate BM aspirate cannot be obtained and there are fewer than 1,000/uL
      PB blasts, the patient is not eligible for AALL08B1 or a frontline COG ALL
      clinical trial (there are NO exceptions to this rule)

   - Patient has suspected ALL:

      - Patients whose blast morphology is obviously myeloid, or whose blasts are
      myeloperoxidase positive, should not be enrolled on AALL08B1; however, patients
      with true biphenotypic or bilineage leukemia (i.e., patient presents with blasts
      with significant expression of multiple lymphoid and myeloid markers such that
      assignment to a single lineage is not possible) are eligible to enroll in
      AALL08B1 for cell banking

   - Samples must be sent to a COG-approved cytogenetics laboratory, and COG Reference
   Laboratory studies; if informative results needed for treatment stratification are not
   available at specified time-points during induction, patients will not be eligible to
   receive post-induction therapy on a COG ALL trial

   - All patients and/or their parents or legal guardians must sign a written informed

   - All institutional, Food and Drug Administration (FDA) and National Cancer Institute
   (NCI) requirements for human studies must be met

Exclusion Criteria:

   - Patient must not have received prior cytotoxic therapy except for steroids or
   intrathecal chemotherapy

   - Patient must not have secondary ALL that developed after treatment of a prior
   malignancy with cytotoxic chemotherapy

Ages Eligible for Study

N/A - 30 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer Marcellus
Not Recruiting